GlassScriptPhysician profile
Kurtis A Hull
NPI 1255350674
$3,627.63
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $1,541 · 2021: $831 · 2022: $29.62 · 2023: $27.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $587.68 | 2019-2022 | |
| Abbvie INC. | $461.35 | 2019-2023 | |
| Amarin Pharma, INC. | $352.79 | 2019-2021 | |
| Allergan, INC. | $295.48 | 2020 | |
| Glaxosmithkline, LLC. | $286.58 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $236.42 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.22 | 2019-2021 | |
| Amgen INC. | $137.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $128.57 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.92 | 2019-2021 | |
| Lilly USA, LLC | $111.02 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $105.80 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $90.32 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.95 | 2019-2020 | |
| Pfizer INC. | $75.56 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $53.04 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $47.97 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $45.73 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $32.05 | 2020 | |
| Eisai INC. | $26.53 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $26.30 | 2020 | |
| Biogen, INC. | $24.40 | 2020 | |
| Astellas Pharma US INC | $20.85 | 2019 | |
| Daiichi Sankyo INC. | $14.50 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.73 | 2021 | |
| Horizon Therapeutics Plc | $12.10 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurtis Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.